

1,4-Dihydropyridines: A Multifunctional Molecule- A Review

G.Swarnalatha*, G.Prasanthi, N.Sirisha, C.Madhusudhana Chetty

Department Of Pharmaceutical Chemistry, Annamacharya College of Pharmacy,
New Boyanapalli, Rajampet, Kadapa-516126, Andhra Pradesh, India.

**Corres.author: swarna.pharmacy@gmail.com, Mobile No: 09542873967*

Abstract: 1,4-dihydropyridine is the most feasible heterocyclic ring with various substitutions at several positions. This molecule binds to the L-type calcium channel and act as a multifunctional lead molecule for the various Cardiovascular activities which include Antihypertensive, Antianginal, vasodilator and cardiac depressants activities. Apart from the CVS activities it also exhibit antitubercular ,anticonvulsant, antitumour ,analgesic, anti-inflammatory , stress protective activities. The present review highlights the various synthetic routes with specified structural activity features with corresponding pharmacological activities.


Keywords: 1,4-dihydropyridines, cvs activitites, other activities.

Introduction:

1,4-dihydropyridine is a six membered aromatic ring containing N at 1st postion ,which is saturated at 1 and 4th position are 1,4-DHP . the most feasible position for substitution is 4th which exhibit various activities i.e., as the calcium channel antagonists [1] and the heterocyclic ring is the common feature for various pharmacological activities such as antihypertensive , antianginal [2-4],antitumor [5],anti-inflammatory activity [6,7], antitubercular activity[8],analgesic activity [9], antithrombotic [10,11]. It binds to L-type channel and also shows action by binding to N-type channel also [12].other activities like vasodilation [13], anticonvulsant [14].stress protective effect [15], cardio depressant activity [16]. Biological activity of various 1, 4-dihydropyridines derivatives have been published in various papers and their brief review is given in this paper.


Chemistry:

Various methods have been proposed by various scientists for the synthesis of 1,4-dihydropyridine. Synthesis of 1,4-dihydropyridines was first reported by Hantzsch by refluxing of aldehyde, β -ketoester and ammonia or ammonium salts in ethanol.(scheme-1)[17]




Scheme-1

Some other have reported the one-pot synthesis of 1,4-DHP with 3-component (aldehyde, alkylacetoacetate, ammonia) by refluxing with methanol gives good yield (scheme-2) [18].




Scheme-2

An efficient one-pot synthesis of polyhydroquinolines by reaction of aldehyde, ethylacetoacetate, dimedone, ammonium acetate, in presence of the MCM-41 as catalyst by using grinding method have been reported (scheme-3) [19].




Scheme-3

Some other authors have reported the preparation of 1,4-dihydropyridines using catalyst alumina sulphuric acid by condensing aldehydes, 1,3-dicarbonyl compounds, and ammonium acetate (scheme-4) [20].



Scheme-4


A new synthesis have reportd for 1,4-DHP under ultrasound irradiation with out solvent and catalyst and get higher yield at shorter time(scheme-5)[21].



Scheme-5

Structure Activity Relationship(SAR):

The detail study on the structural features of 1,4-DHP as lead compound have been described[22,23].




Structure of 1, 4-Dihydropyridine.

1. The 1,4 DHP ring is essential for activity.
2. The unsaturation of the basic ring will decrease the activity.
3. Substitution at N₁ Position or the oxidized (Piperidine) or reduced (pyridine) ring system greatly decreases or abolishes the activity .
4. The 2,6 –Substituents of 1,4-DHP rimd should be Lower, alkyl, and one NH₂ group is tolerated.
5. Ester groups at C₃ and C₅ position shows optimum activity .The presence of electron withdrawing groups shows decreased antagonistic activity and may even shows agonist activity .
EX: Isradipine
Removal or replacement by COMe orCN greatly reduces activity
6. Ester substitution larger than COOMe greatly maintain or even increases the activity because of bulk tolerance in the site of 1,4-DHP
Ex: Amlodipine. C₃-methyl, c₅ ethyl.
7. Ester at C₃ andC₅ are non identical ,the C₄ carbon becomes chiral and stereo selectivity between the enantiomers is observed.
8. Substitution of phenyl ring at C₄ position has optimum activity.
9. Substitution of small non planar alkyl or cyclo alkyl group shows decreased activity .
10. Compound with ortho or meta substitution posses optimum activity,while unsubstituted or a para substitution show decrease in activity according to their electronic and steric effect.

Pharmacological Activities:**Antituberculosis activity:**

Antituberculosis activity of some 4-substituted-2,6-dimethyl-3,5-bis-N-(heteroaryl)-carbamoyl-1,4-dihydropyridines have studied and the compound with 2-Pyridyl at 4th position and 6-methylpyridin-2-yl at 3 & 5th position 1a (IC₅₀ = 12.5 µg/mL) is more potent than control pyrazinamide (IC₅₀ = 32 µg/mL) and 2-Imidazolyl at 4th position and 5-chloropyridin-2-yl at 3 & 5th position 1b (IC₅₀ = 25 lg/mL) exhibit good activity and almost equipotent to pyrazinamide (IC₅₀ = 32 µg/mL) [24].(scheme:6)


**Scheme-6**

A series of symmetrical, asymmetrical & unsubstituted 1,4-dihydropyridines have studied for antituberculosis activity (against mycobacterium tuberculosis H₃₇ strains. The highest activity was observed for the 4-(4-(Dimethylamino)phenyl)-1,4-dihydro-N³,N⁵-bis(2-methoxyphenyl)-2,6-dimethylpyridine-3,5-dicarboxamide shows 93% & 4-(2-Hydroxyphenyl)-1,4-dihydro-N³,N⁵-bis(3-nitro-phenyl)-2,6-dimethylpyridine-3,5-dicarboxamide shows 92% of inhibition because of the presence of 2-methoxy and 3-nitro groups on the carbonyl moiety and 4 N(CH₃)₂ and 2-OH on the aryl ring. The other compounds like 4-(4-Chlorophenyl)-1,4-dihydro-N³,N⁵-bis(3-chloro-4-fluorophenyl)-2,6-dimethylpyridine-3,5-dicarboxamide shows 88% of inhibition because of 3-chloro and 4-fluoro substitution in the carbonyl side chain and m-chloro on phenyl ring and 4-(4-Chlorophenyl)-1,4-dihydro-N³,N⁵-bis(3-chloro-phenyl)-2,6-dimethylpyridine

3,5-dicarboxamide shows 85% because of 2-chloro substitution in carbonyl side chain 4-chloro in phenyl ring [25]. similar studies have been performed for series of 4-Substituted Phenyl-2,6-dimethyl-3,5-Bis-N-(substituted Phenyl)carbamoyl-1,4-dihydropyridines. The compounds substituted with NO₂ group or 2-Cl or OCH₃ at 3 and 4 position of phenyl carbonyl ring exhibit >90% of inhibition against H₃₇ RV in comparison with rifampicin [26].

Some of the novel 4-substituted imidazolyl-2,6-dimethyl-N³,N⁵-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides have studied for the antituberculosis activity against M.tuberculosis H₃₇RV strain. The compound 4-(1-Benzyl-2-(methylthio)-1H-imidazol-5-yl)-2,6-dimethyl-N³,N⁵-bis(4-chlorophenyl)-1,4-dihydropyridine-3,5-dicarboxamide is as potent as rifampicin and 4-(1-Benzyl-2-(methylthio)-1H-imidazol-5-yl)-2,6-dimethyl-N³,N⁵-bis(pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxamide shows potent activity (MIC-2µg/ml) [27].


In the same way a new series of N³,N⁵-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamides have screened for the antituberculosis activity against m.tuberculosis (H₃₇Rv) and the compound with 3-chlorophenyl group at 3,5 dicarbox-amide position was the most active compound & the compounds with 3-Nitrophenyl and 4-nitrophenyl compound are relatively active compared to rifampicin [28](scheme-7).

**Scheme-7**

A series of N^3, N^5 -Diaryl-4-(5-arylisoxazol-3-yl)-1,4-dihydropyridine-3,5-dicarboxamide have tested for same activity and the compound N^3, N^5 -bis-(4-methoxy-2-nitrophenyl)-2,6-dimethyl-4-(5-phenylisoxazol-3-yl)-1,4-dihydropyridine-3,5-dicarboxamide exhibit good activity [29].

Antimicrobial activity :


The antimicrobial activity was performed against various bacteria, fungi, other microorganism by paper disc method & cup and plate method. Agar was used to culture the test bacteria and Potato Dextrose Agar was used to culture fungi. The microbial culture were grown at 37°C for 8 hours and then appropriately diluted with sterile 0.8% saline solution. The concentration of test drugs was kept 200 µg/ml in DMF. Standard drugs Novobiocine, Gentamycin, Kanamycin, Amikacin (for antibacterial) and Ampicilline (for antifungal) were used for comparison. The Antimicrobial activity was evaluated by measuring the zone of growth inhibition around disc of test organism. A new series 4-substituted-2,6-dimethyl-3,5-bis-N-(heteroaryl)-carbamoyl-1,4-dihydropyridines have been screened for the antibacterial activity gram +ve bacteria (*Bacillus subtilis* and *Staphylococcus aureus*) and gram – ve bacteria (*Escherichia coli* and *Proteus vulgaris*). 4-(2-Pyridyl)-2,6-dimethyl-3,5-bis-N-(6-methylpyridin-2-yl)-carbamoyl-1,4-dihydropyridine(8a) exhibit almost equal activity to streptomycin against gram negative bacteria and the compound 4-(2-Imidazolyl)-2,6-dimethyl-3,5-bis-N-(2-methyl-4-oxo-3H-quinazolin-3-yl)-carbamoyl-1,4-dihydropyridine (8b) exhibit more potent activity against *Bacillus subtilis* (**scheme -8**)[24].



Scheme:8

Some other 4-substituted 3-(4,4-dimethyl-oxazolin-2-yl)-1,4-dihydropyridylacetic acids derivatives have been screened against Gram-Positive bacteria and only few analogs shows moderate antibacterial activity [30].

A series of N-(6-methylbenzothiazolyl)-2,3,5,6-tetrasubstituted-4-(aryl)-1,4-dihydropyridines have been evaluated for antibacterial, antifungal, and Entomological activity. The compounds N-(6-methylbenzothiazolyl)-3,5-dicarbethoxy-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine 9a, N-(6-methylbenzothiazolyl)-3,5-dicarbethoxy-2,6-diethoxy-4-(m-nitrophenyl)-1,4-dihydropyridine 9b, N-(6-methylbenzothiazolyl)-3,5-diacetyl-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine 9c exhibit highest activity against various bacterial strains like *Lactobacillus* sps, *Pseudomonas aeruginosa*, *Micrococcus luteus* and *Kocuria rosea* when compared to standard drug like kanamycin, gentamycin, novobiocin. and also shows potent activity against fungal sps like *Aspergillus niger* and *Aspergillus candidus* compared to standard Ampicillin drug. The other compounds like N-(6-methylbenzothiazolyl)-3,5-dicarbethoxy-2,6-dimethyl-4-(p-methoxyphenyl)-1,4-dihydropyridine 9d, N-(6-methylbenzothiazolyl)-3,5-diacetyl-2,6-dimethyl-4-(p-methoxyphenyl)-1,4-dihydropyridine 9e, N-(6-Methyl-benzothiazolyl)-3,5-dicarbethoxy-2,6-diethoxy-4-(p-methoxyphenyl)-1,4-dihydropyridine 9f, N-(6-methylbenzothiazolyl)-3,5-diacetyl-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine 9g exhibit highest antifeedent activity fourth instars larvae of *Spodoptera litura*. The compound N-(6-methylbenzothiazolyl)-3,5-dicarbethoxy-2,6-diethoxy-4-(p-hydroxyphenyl)-1,4-dihydropyridine shows highest acaricidal activity against *Tetranychus urticae* of mites (**scheme-9**) [31].



Scheme-9


	R ₁	R ₂	R ₃
9a.	Me	O=COEt	m-NO ₂
9b.	Oet	O=COEt	m-NO ₂
9c.	Me	COMe	m-NO ₂
9d.	Me	O=COEt	p-OMe
9e.	Me	COMe	p-OMe
9f.	Me	COMe	p-OH
9g.	Me	COMe	m-NO ₂

Some other scientist have studied the antifungal activity of dihydropyridine derivatives against aspergillus fumigates ,candida albicans .The compound diethyl 4-(4-methoxyphenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarboxylate exhibit significant and appreciable activity against A.fumigatus and the compound dimethyl 4-(4-methoxyphenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarboxylate significant activity against A.fumigatus in disc diffusion, microbroth dilution and percent spore germination inhibition assay but these are less potent when compared to standard drug Amphotericin B [32]. The compound 2,6-dimethyl-4-phenyl-pyridine-3,5-dicarboxylic acid diethylester has been isolated from natural source jatropa elliptica belongs to family euphorbiacea.This compound have screened for antibacterial activity and it shows enhancing antibacterial activity against Staphylococcus aureus possessing the MsrA and NorA resistance efflux mechanisms [29]. Similar studies have performed for 4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-1,4-dihydropyridines in various bacterial strains that is Proteus vulgaris , P.aeurginosia , E.coli. The compound 4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3-ethyl-5-methyl dicarboxylate shows good activity with reference to gentamycin[33].

Anticancer activity:

The anticancer activity of 4-substituted-2,6-dimethyl-3,5-bis-N-(heteroaryl)-carbamoyl-1,4-dihydropyridines have been studied and the compound 4-Chlorophenyl at c₄ position and 2-methyl-4-oxo-3H-quinazolin-3-yl substitution at c₃ & c₅ position of 1,4-dihydropyridine have shown the equipotent activity compared to methotrexate drug against MCF-7 and HT-29 cell lines [24].


A new 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP-7) ,which is a novel multidrug resistance inhibitor, and it is investigated in lagendorff-perfused rat heart and compared with that of nifedipine .The result showed that DP7 is a lead compound foe the design of novel ,safe ,potent MDR chemosensitizer [34]. Other authours have studied the substituted 4-phenyl-3,5-dibenzoyl-1,4-dihydropyridines derivatives for the cytotoxic activity and MDR-reversing activity .The results showed that the compounds with 2'-trifluoromethylphenyl 10a, 2'-chlorophenyl (IC₅₀=7.0μm) 10b,3 -chlorophenyl (IC₅₀=7.0μm) 10c at c₄ position, have shown the highest cytotoxic activity against HSC-2 cell lines. The compound 10c also shows the high MDR-modulating activity and tumour –specific cytotoxicity, so it is recommended as new drug for cancer treatment (**scheme-10**) [35].



	R
10a	2-cf3
10b	2-cl
10c	3-cl

Scheme-10

The antitumour activity of several newly synthesized 1,4-dihydropyridines have been screened by using mice carrying P388 leukemia cells *in vivo*. The results shows that the compound N276-9 , N276-16 was found to be the active compound to overcome the multidrug resistance because of the presence of 3-pyridylpropylesters (scheme-11)[36].




Scheme-11

Some of the scientists have studied the β -carbonyl-1, 4-dihydropyridine series (AV-153 or sodium 3, 5-bis-ethoxycarbonyl-2,6-dimethyl-1,4-dihydropyridine-4-carboxylate) with high genoprotective activity in order to determine DNA repair and apoptosis. The results indicate that AV-153 have high efficiency in stimulating DNA repair and also modulate apoptosis in human cells .In this peripheral blood lymphocytes of healthy donors are used instead of cell lines [37]. The compound 2,6-dimethyl-4-phenyl-pyridine-3,5-dicarboxylic acid diethyl ester has been isolated from natural source *Jatropha elliptica* belongs to family *Euphorbiaceae*. This compound have screened for cancer activity and it shows enhancing anticancer activity[38].


Antioxidant activity:

The antioxidant activity of a series of 2,6-dimethyl-3,5-dialkoxycarbonyl-1,4-dihydropyridines possessing various side chain length alkyls (CH_3 - $\text{C}_{16}\text{H}_{33}$) in ester moiety were evaluated in transition metal-ion catalysed liposome peroxidation .The compounds 2,6-dimethyl-3,5-diethyloxycarbonyl-1,4-dihydropyridines 12a and 2,6-dimethyl-3,5-dibutyloxycarbonyl-1,4-dihydropyridines 12b exhibit high activity when compare with antioxidant activity of Trolox and probucol (scheme-12)[39].



Scheme-12

Similar studies have been studied in a series of novel 5-acetyl-2-alkylthio-4-aryl-6-methyl-1,4-dihydropyridine-3-carboxylic acid nitriles .The results conclude that the compound 3,4-dihydrophenyl at 4th position is the most active compound compared with the standard antioxidant activity of trolox because of the presence of dihydroxy phenyl substitution at 4-position (scheme-13)[40].



Scheme-13

Another scientists have studied the antioxidant activity of N-aryl-1, 4-dihydropyridines. The compounds 2-Methyl-1,4-diphenyl-1,4-dihydro-pyridine-3-carboxylic acid tert-butyl ester and 1-(4-Chlorophenyl)-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid tert-butyl ester shows significant antioxidant activity because of the presence of tertiary butyl ester group[41].

Cardiovascular activity:

The antihypertensive activity of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5- position are studied and the compound 2-nitrooxypropyl 3-nitrooxypropyl -2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate (CD-349) was more potent antihypertensive activity when compared to nifedipine[42]. The same activity is done on some new nitroxyalkyl 1,4-dihydropyridine derivatives in rat Model of Two-Kidney ,One-Clip Hypertension and the results showed that the compound containing two nitroxy groups had poor effect of decreasing in Men Arterial pressure compared to nifedipine [43].


A series of novel 4-[1-(4-x-benzyl)-5-imidazolyl] dihydropyridines have been screened for the antihypertensive activity in desoxycortisone acetate induced in hypertension in rats. The compound 1, 4 – dihydro – 2, 6 – dimethyl – 4 - [1-(4-fluro-benzyl)-5-imidazolyl] – 3 , 5-pyridinedicarboxylate shows most active activity than that of amlodipine because of presence of electron withdrawing groups at Para position of benzyl ring [44]. Some authours have reported the antihypertensive effect 3-(4-Allyl-1-piperazinyl)-2, 2-dimethylpropyl methyl 1, 4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridinedicarboxylate dihydrochloride (NKY- 722) which is a new water- soluble 1,4-dihydropyridine derivative produces a dose dependent activity in conscious spontaneously hypertensive rats (SHR). After administration of NKY-722, at a dose of 3 mg/kg, the peak decrease in blood pressure recorded was 50±8mmHg (n=5),while the nifedipine was only 18±3mmHg (n=5) and it shows prolonged action 8hr at 1 and 3 mg/kg [45].

Similar activities are performed for stereo isomers of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester which is a highly potent calcium antagonist, the compounds are separated in to stereo and optical isomers and their antihypertensive activity are screened , the results showed the alpha isomer is more potent than beta isomer , the hypotensive effect of (+)-alpha, namely (S)-(S)-1, was 30 to 100 times stronger than that of (-)-alpha in intravenously administered spontaneously hypertensive rats [46].

In the same way antihypertensive activity of novel 1,4-dihydropyridine derivatives bearing 3-[4-(substituted amino) phenylalkyl]ester derivatives have been studied . The results showed that most compound are potent and a longer duration of action . 2-[4-(4-benzhydryl -1-piperazinyl) phenyl]ethyl methyl 1,4-dihydro -2,6-dimethyl -4-(3-nitrophenyl)-3,5-pyridinedicarboxylate ,its analogs 4-(4-cyno-2-pyridyl) , 3-[4-(4-benzhydryl -1-piperazinyl)phenyl]propyl ester analogue , 2-[4-(4-benzhydryl-1- piperidinyl)phenyl]ethyl ester analogue , 2-[4-(1-benzhydryl-4-piperidinyl)phenyl]ethyl ester analogue shows good activity and these are used for further pharmacological investigations[47]. A series of new 1,4-dihydropyridne derivatives with 4-(disubstituted phenyl and an amino ethyl ester or an amino -2,2-dimethyl –propyl ester groups are evaluated for antihypertensive activity

in normotensive rats and spontaneously hypertensive rats. Most of the compounds showed a more potent activity and longer duration of action than nifedipine. The compound TC -81 showed highly potent and long lasting activity [48]. A novel 2-amino-1,4-dihydropyridine derivatives with nitroxy-alkoxycarbonyl groups at 3-and /or 5-position were screened for antihypertensive activity in spontaneously hypertensive rats. the compound with tertiary amino group at either side of an ester chain shows potent and prolonged duration of action [49]. Symmetrical and unsymmetrical substitution of 1,4-dihydropyridine derivatives have studied for calcium channel blocking activity i.e., antihypertensive activity. the compound with 4-trimethoxy phenyl, 4- [3-methoxy,4-benzyloxy phenyl], 4-[3-methoxy,4-hydroxy phenyl] at c₄ position have shown the good activity compared with standard felodipine [50]. Calcium antagonistic activity of 1,4-dihydro-2,6-dimethyl-4-(5-phenylisoxazol-3-yl) pyridine-3,5-dicarboxylate were studied using the high k⁺ concentration of guinea-pig ileum longitudinal smooth muscle assay. The results indicates that synthesized compounds exhibit less potent activity (10⁻⁵-10⁻⁷) compared to nifedipine (IC₅₀=1.10±0.40 X 10⁻⁸) [51]. Similar activities have been studied in lipophilic nitroimidazolyl-1,4-dihydropyridines. It states that the lipophilic aromatic substitution at the c-6 position of dihydropyridine ring are supposed to improve penetration in to the organs, but substitution of aromatic ring at both c-2 and c-6 position of DHP by replacing both methyl groups shows lower calcium antagonistic activity, due to increased steric hindrance. It also showed that the compound 5-ethyl-3-n-propyl-1,4-dihydro-2-methyl-6-phenyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5pyridine dicarboxylate, 5-ethyl-3-n-butyl -1,4-dihydro-2-methyl-6-phenyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5pyridine Dicarboxylate, 5-ethyl-3-isobutyl-1,4-dihydro-2-methyl-6-phenyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5pyridine dicarboxylate exhibit higher activity, due to increased alkyl chain at c-3-position (scheme-10) [52]. Similar activity is studied in Isobutyl Methyl 2,6-Dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (Nisoldipine) Series, it also studied the radio ligand bioassay. The results showed that the compounds are approximately 10-fold more active in the radio ligand bioassay than the pharmacological assay, and also the pharmacological action increases with increasing ring planarity [53].

Some of the authors have studied the 1,4-dihydropyridines containing phenylaminoimidazolyl substituents for their calcium antagonist activity. some of the compounds with Diethyl 14a and diphenyl 14b at 3 & 5th carbon and 2-methylthio-1-phenylamino-5-imidazolyl at 4th carbon were more active than nifedipine. It concluded that the increasing the alkyl ester chain at c-3 and c-5 position with more than two alkyl groups decrease the activity (scheme-14)[54].




Scheme-14


Anticonvulsant activity :

A new series of 1,4-dihydropyridines have been screened for the anticonvulsant activity by Maximal Electroshock Induced convulsions in Rats, PTZ induced convulsions in Rats, and Strychnine induced Convulsions in Rats methods. All the synthesised compounds have been found to exhibit good anticonvulsant activity [55].

Anticonvulsant activity of Alkyl, cycloalkyl and aryl alkyl ester analogues of nifedipine in which the ortho-nitro phenyl group at position 4 is replaced by 1-methyl-4-nitro-5-imidazolyl substituent have seen determined against pentylenetetrazole-induced convulsions in mice. The results showed that most of the compound were more potent than nifedipine [56].



No.	R	N
a	CH ₃	0
b	CH ₃	1
c	C ₆ H ₅	1
d	C ₆ H ₅	2




NO	R ₁	R ₂
a	CH ₂ CH ₂ CH ₂ C ₆ H ₅	CH ₃
b	CH ₂ CH ₂ CH ₂ C ₆ H ₅	CH ₂ CH ₃
c	CH ₂ C ₆ H ₁₁ (Cyclohexyl)	CH ₃
d	CH ₂ CH ₂ C ₆ H ₁₁ (Cyclohexyl)	CH ₃

Other activities:

Antidyslipidemic activity:


The antidyslipidemic activity of N-aryl-1,4-dihydropyridines have been studied and the compounds 2-Methyl-1,4-diphenyl-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 15a, 2-Methyl-1,4-diphenyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester 15b, and 1-(2,3-Dimethyl-phenyl)-2,5-dimethyl-4-phenyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester have exhibit the good lipid and TG lowering activity (scheme-15)[41].




Scheme-15

Analgesic & Anti-inflammatory activity:

Some other 1,4-dihydropyridine derivatives were found to possess analgesic and anti-inflammatory activity and the compounds have almost equipotent activity compared to piroxicam at a dose of 70mg/kg body wt(scheme-16)[57].

**Scheme-16****Antiulcer activity:**

A novel 1,4-dihydropyridines and their mannich bases with sulfanilamide are studied for antiulcer activity and the compound containing methoxy substitution at c-4 position shows good antiulcer activity(scheme-17)[58].

**Scheme-17**

Conclusion:

The present review concludes that 1,4-DHP as a Multifunctional potent lead Molecule, which has various feasible positions for substitution and exhibit several pharmacological activities such as calcium channel antagonist activity, antihypertensive activity, vasodilator activity, antianginal activity and apart from CVS activities it also exhibit other pharmacological activities such as antitubercular activity ,antibacterial activity, anti-inflammatory activity, anticonvulsant activity,antiulcer activity and soon.

References:

- David J. Triggle. Calcium channel antagonists: Clinical uses—Past, present and future. *Biochemical Pharmacology*, 2007, 74, 1-9.
- Love. B, Goodman. M, Snader. K, Tedeschi. R, Macko. E. Hantzsch-type dihydropyridine hypertensive agent., *J. Med. Chem.* 1974, 17, 956-965.
- Bossert. F, Meyer .H, Wehinger. E. 4-Aryldihydropyridines, a new class of highly active calcium antagonists. *Angew. Chem. Int. Ed. Engl.* 1981, 20, 762-769.
- Breitenbucher. J.G., Figliozz . G. Solid-phase synthesis of 4-aryl-1,4-dihydropyridines via the Hantzsch three component condensation. *Tetrahedron Lett.* 2000, 41, 4311-4315
- Boer. R & Gekeler .V. chemosensitiser in tumour therapy: new compounds promise better efficacy , *Drugs Fut*, 1995, 20, 499-509.
- Briukhanov .V .M. The effect of Ca antagonist on the development of inflammatory edema in rats. *Exp .clin .pharmacology* ,1994 , 57 , 47-49.
- Bahekar Sushilkumar, Shinde Devanand. Synthesis and anti-inflammatory activity of 1, 4-dihydropyridines. *Acta pharmaceutica (Zagreb) A.* 2002, 52(4), 281-287.
- Wachter .G. A , Davis M.C. Antimycobacterial activity of substituted isosters of pyridines and pyrazine carboxylic acids. *J med chem.* ,1998, 41, 2436-2438.
- S.Gullapalli, P.Ramarao. L-type Ca²⁺ channel modulation by dihydropyridines potentiates- κ -opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats. *Neuropharmacology*, 2002, 42, 467–475.
- Sunkel. C.E, De casa Juana.M.F, Santos.L. 4-alkyl-1,4-dihydropyridines as specific PAF-acether antagonists . *J med chem.*, 1990, 33, 3205-3210.
- Ono Handkinura. M. Effect of Ca⁺²antagonist, vasodilators, diltizem, nifedipine, perhexiline and verapamil on platelet aggregation invitro. *Arzneim-forsch Drug Res*, 1981, 3, 1131-1134.
- David J. Triggle. The pharmacology of ion channels: with particular reference to voltage-gated Ca⁺² channels. *European Journal of Pharmacology* , 1999, 375, 311–325.
- Wilson and Giswold., *Text Book Of Organic medicinal and Pharmaceutical Chemistry*,11th Edition ,628.
- Tusell J.M, Barron.s and Seratosa .J. Anticonvulsant activity of -HCH, calcium channel blockers and calmodulin antagonists in seizures induced by lindane and other convulsant drug. *Brain Res*, 1993, 622, 99-104.
- L. M. Tarasenko, K. S. Neporada, and V. Klusha. Stress-Protective Effect of Glutapyrone Belongingto a New Type of Amino Acid-Containing 1,4-Dihyropyridines on Periodontal Tissuesand Stomach in Rats with Different Resistance to Stress. *Bulletin of Experimental Biology and Medicine*, 2002 , 133(4), 426-428.
- Roberta Budriesi, Pierfranco Ioan , Alessandra Locatelli .Imidazo[2,1-*b*]thiazole System: A Scaffold Endowing Dihydropyridines with Selective Cardiodepressant Activity. *J. Med. Chem.* 2008, 51, 1592–1600
- Hantsch .A et.al. Hantzsch pyridine synthesis. *Ann Chem.*,1882,215,1-81.
- D .R.Harish kumar, Nayeem Naira et.al. Synthesis and invitro calcium channel blocking activity of symmetrical and unsymmetrical substituted 1,4-dihydropyridines. *Asian journal of Chemistry*, 2009, vol 6, 21,4357-4365.
- V. M. Markhele, S.A. Sadaphal and M. S. Shingare. An Efficient One-Pot Synthesis of Polyhydroquinolines at RoomTemperature Using MCM-41 catalyst under solvent-free

- conditions. Bulletin of the Catalysis Society of India, 6 (2007) 125-131.
20. Mustafa Arslan *et.al*. An efficient one pot synthesis of 1,4-dihydropyridines using alumina sulfuric acid (ASA) catalyst. Turk J Chem 33 (2009) , 769 – 774.
 21. Shu-Xiang Wang, Zhi-Yan Li, Jin-Chao Zhang, Ji-Tai Li. The solvent-free synthesis of 1,4-dihydropyridines under ultrasound irradiation without catalyst. Ultrasonics Sonochemistry 15 (2008) 677–680
 22. David J. Trigg. 1,4-Dihydropyridines as Calcium Channel Ligands and Privileged Structures Cellular and Molecular Neurobiology. June 2003,23(3),293-303.
 23. Nicoletta Pedemonte, Davide Boido. Structure-Activity Relationship of 1,4-dihydropyridines as potentiators of the cfr chloride channel. Molecular Pharmacology Fast Forward ,2007.
 24. Kalam Sirisha , Garlapati Achaiah, and Vanga Malla Reddy. Facile Synthesis and Antibacterial, Antitubercular, and Anticancer Activities of Novel 1,4-Dihydropyridines. Arch. Pharm. Chem. Life Sci. 2010, 343, 342 – 352
 25. Atul .T. Manvar, · Raghuvir .R. S. Pissurlenkar. Synthesis, in vitro antitubercular activity and 3D-QSAR study of 1,4-dihydropyridines, Mol Divers , 2010, 14, 285–305.
 26. Bhavik Desai, Dinesh Sureja, Yogesh Naliapara , Anamik Shaha and Anil K. Saxena. Synthesis and QSAR Studies of 4-Substituted Phenyl-2,6-dimethyl-3, 5-Bis-N-(substituted Phenyl)carbamoyl-1,4-dihydropyridines as Potential Antitubercular Agents. Bioorganic & Medicinal Chemistry, 2001, 9, 1993–1998.
 27. Afshin Fassihi, Zahra Azadpour, Neda Delbari. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2, 6-dimethyl-N³, N⁵-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides, European Journal of Medicinal Chemistry, 2009, 44, 3253–3258.
 28. Amini M, Navidpour L, Shafiee A. Synthesis and antitubercular activity of new N,N-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamides, DARU, 2008, 16(1), 9-12.
 29. B. Shafii, M. Amini, T. Akbarzadeh, and A. Shafiee. Synthesis and Antitubercular Activity of N³, N⁵-Diaryl-4-(5-arylisoxazol-3-yl)-1, 4-dihydropyridine-3, 5-dicarboxamide. Journal of Sciences, Islamic Republic of Iran, 2008, 19(4), 323-328.
 30. Sushil.K.Dubey and Edward.E. Knaus. Synthesis of heterocyclic 1,4-dihydropyridylacetic acid derivatives of 6-aminopenicillanic acid and D-aminobenzylpenicillin with antibacterial activity. Can. J. Chem., 1984, 62, 559.
 31. Mithlesh, Pawan.K. Pareek, Ravi Kant, Sanjeev .K. Shukla, Krishan G. Ojha. Rapid synthesis and biological evaluation of 1, 4-dihydropyridine derivatives containing a benzothiazolyl moiety. Cent. Eur. J. Chem, 2010, 8(1), 163–173.
 32. Anil K. Chhillar, Pragma. Arya. Microwave-assisted synthesis of antimicrobial dihydropyridines and tetrahydropyrimidin-2-ones: Novel compounds against aspergillosis. Bioorganic & Medicinal Chemistry, 2006, 14, 973–981.
 33. Rakesh kumar, sakshi malik, & Ramesh Chandra. synthesis and antimicrobial activity of 4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-1,4-dihydropyridines and 4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-3,4-dihydropyrimidin-2-ones. Indian journal of chemistry ,May2009, 48, 718-724.
 34. Simona Saponara , Antonella Ferrara , Beatrice Gorelli , Anamik Shah .3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine(DP7): A new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart. European Journal of Pharmacology 2007, 563, 160–163.
 35. Masami Kawase, Anamik Shah , Harsukh Gaveriya, Noboru Motohashi, Hiroshi Sakagami, Andreas Vargae and Joseph Molna R. 3,5-Dibenzoyl-1,4-dihydropyridines: Synthesis and MDR Reversal in Tumor Cells, Bioorganic & Medicinal Chemistry , 2002, 10 1051–1055.
 36. Shigeyuki Tasaka, Hiromasa Ohmori, Noriaki Gomi, Mayumi Iino, Tosiki Machida, Akira Kiue, Seiji Naito and Michihiko Kuwanoc. Synthesis and Structure Activity Analysis of Novel Dihydropyridine Derivatives to Overcome Multidrug Résistance. Bioorganic & Medicinal Chemistry Letters , 2001, 11, 275-277.

37. Nadezhda I. Ryabokona, Nataliya V. Nikitchenkob, Olga V. Dalivelyab, Rose I. Goncharovab, Gunars Dubursc, Maria Konopackaa, Joanna Rzeszowska-Wolnya. Modulation of cellular defense processes in human lymphocytes in vitro by a 1,4-dihydropyridine derivative, *Mutation Research*, 2009, 679, 33–38.
38. Be'atrice Marquez, Luc Neuville, Nicole J. Moreau, Jean-Pierre Genet, Aldenir Feitosa dos Santos. Multidrug resistance reversal agent from *Jatropha elliptica*, *Phytochemistry*, 2005, 66, 1804–1811.
39. Gunars Tirzitis, Dace Tirzitis and Zhanna Hyonen. Antioxidant activity of 2,6-dimethyl-3,5-dialkyloxycarbonyl-1,4-dihydropyridines in metal ion catalysed lipid peroxidation, *Czech.J.Food Sci*, 2001, 19(3), 81-84.
40. D. Tirzite, A. Krauze, A. Zubareva, G. Tirzitis, and G. Duburs. Synthesis and Antiradical activity of 5-acetyl-2-alkylthio-4-aryl-6-methyl-1,4-dihydropyridine-3-carboxylic acid nitriles, *Chemistry of Heterocyclic Compounds*, 2002, 38(7), 795-800.
41. Atul Kumar, Ram Awatar Maurya, Siddharth Sharma, Mukesh Kumar, Gitika Bhatia. Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents, *European Journal of Medicinal Chemistry*, 2010, 45, 501–509.
42. Toshihisa Ogawa, Atsuro Nakazato, Katsuharu Tsuchida, and Katsuo Hatayama. Synthesis and antihypertensive activity of new 1,4-dihydropyridine derivatives containing nitroxyalkylester moieties at the 3- and 5-position, *chem.Pharm.Bull.*, 1993, 41(6), 1049-1054.
43. Ali Akbar Nekooeian, Azadeh Khalili, Katayoun Javidnia, Ramin Miri. Antihypertensive effect of some new nitroxyalkyl 1,4-dihydropyridines derivatives in rat model of two-kidney, one clip hypertension, *Iranian journal of pharmaceutical research*, 2009, 8(3), 193-199.
44. F.Hadizadeh, Z.Fatehi-Hassanabad, M.Fatehi-Hassanabad, and F.nabati. Synthesis and antihypertensive activity of novel 4-[1-(4-x-benzyl)-5-imidazolyl] dihydropyridines in rat, *Research in pharmaceutical sciences*, oct 2007, 2(2), 85-90.
45. Seimei Osumi, Shigeyoshi Morishita, Katsuo Wada, Hachiro Usui, Mamoru Kanda, Hiroshi Matsui. Antihypertensive Effect of NKY-722, a new water-soluble 1,4-dihydropyridine derivative, on conscious spontaneously hypertensive rats, *Tohoku J. exp. Med*, 1988, 155, 205-206.
46. Muto K, Kuroda T, Kawato H, Karasawa A, Kubo K, Nakamizo N. Synthesis and pharmacological activity of stereoisomers of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester, *Arzneimittelforschung*. 1988 Nov, 38(11A), 1662-5.
47. Kanno H, Yamaguchi H, Okamiya Y, Sunakawa K, Takeshita. Synthesis and antihypertensive activity of 3-[4-(substituted amino) phenylalkyl]ester derivatives, *chem. Pharm bull (Tokyo)*, 1991, 39(1), 91-99.
48. Kanno H, Yamaguchi. Synthesis and antihypertensive activity of 1,4-dihydropyridine derivatives with a 4-(disubstituted phenyl) ring and an amino alkyl ester group: highly potent and long-lasting calcium antagonists, *Chem.Pharm Bull(Tokyo)* 1992, Aug, 40(8), 2049-54.
49. Kobayashi T. Inoue Y. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridines derivatives having nitroxy-alkoxycarbonyl groups at 3-and/or 5-position, *Chem. Pharm bull (Tokyo)*, 1995, May, 43(5), 788-96.
50. D.R Harish Kumar, Nayeem Naira, Manjunath Gahate. Synthesis and invitro calcium channel blocking activity of symmetrical and asymmetrical substitution of 1,4-dihydropyridine derivatives. *Asian Journal Of Chemistry*, 2009, 21(6), 4357-4365.
51. N.Daryabari, T.Akbarzadesh. Synthesis and calcium antagonist activity of new derivatives of dialkyl 1,4-dihydro-2,6-dimethyl-4-(5-phenylisoxazol-3-yl)pyridine-3,5-dicarboxylate. *J. Iran. Chem. Soc.*, March 2007, 4(1), 30-36.
52. Ramin Miri, Katayoun Javidnia, Hasti Sarkarzadeh and Bahram Hemmateenejada. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist, *BMC*, 2006, 14, 4842-4849.

53. R. Fossheim, A. Joslyn, A. J. Solo, E. Luchowski, A. Rutledge and D. J. Triggle. Crystal Structures and Pharmacologic Activities of 1,4-Dihydropyridine Calcium Channel Antagonists of the Isobutyl Methyl 2,6-Dimethyl-4-(substitutedphenyl)-1,4-dihydropyridine-3,5-dicarboxylate(Nisoldipine) Series. *Journal of Medicinal Chemistry*, 1988, 31(2) ,300-305.
54. A. Zarghi , H. Sadeghi , A. Fassihi , M. Faizi , A. Shafiee . Synthesis and calcium antagonist activity of 1,4-dihydropyridines containing phenylaminoimidazolyl substituents. *Il Farmaco* , 2003, 58 , 1077- 1081.
55. Shashikant R Pattan , Nachiket S. Dighe, Deepak S Musmade, Snehalata K. Tambe, Suwarna H Kale ,Vinayak M Gaware and Purna A Chavan. Synthesis and evaluation of some new substituted 1,4-dihydropyridine derivatives and their anticonvulsant activity. *J. Chem. Pharm. Res.*, 2010, 2(1), 246-252.
56. Abbas Shafiee, Noushin rastkari, Mohammad sharifzadeh. Anticonvulsant activities of new 1,4-dihydropyridine derivatives containing 4-nitroimidazolyl substituents. *DARU*, 2004 12(2), 81-86.
57. Brijeshkunvar Mishra and Richa Mishra. Synthesis of some 1, 4-dihydropyridine derivatives for anti-inflammatory activity, *The Pharmacist*, 2007, 2(1), 13-16.
58. B B Subudhi and P K Panda. Synthesis antiulcer activity of 1,4-dihydropyridines and their mannich bases with sulfanilamide. *Indian Journal Of Chemistry*, 2009,48B, 725-728.
